Table 1.
Comparison of the two clinical scores (French score and PLASMIC score)12, 13, 57 predicting severe ADAMTS13 deficiency
| French score | PLASMIC score | |
|---|---|---|
| Platelet count | <30 G/L (+1) | <30 G/L (+1) |
| Serum creatinine level | <2.25 mg/dL (+1) | <2 mg/dL (+1) |
| Hemolysis | ||
| Indirect bilirubin >2 mg/dL | –a | +1 |
| Or reticulocyte count >2.5% | ||
| Or undetectable haptoglobin | ||
| No active cancer in previous year | –a | +1 |
| No history of solid organ or SCT | –a | +1 |
| INR < 1.5 | –a | +1 |
| MCV < 90 fLb | – | +1 |
| Prediction of severe | 0: 2% | 0‐4: 0%‐4% |
| ADAMTS13 deficiency | 1: 70% | 5: 5%‐24% |
| (Activity <10%)c | 2: 94% | 6‐7: 62%‐82% |
Each item is associated with one point (+1).
INR, international normalized ratio; MCV, mean corpuscular value; SCT, stem cell transplantation.
The French score considered patients with a thrombotic microangiopathy (TMA) syndrome (which includes hemolysis with schistocytes in the definition) and assumes that there is no history of or clinical evidence for associated cancer, transplantation or disseminated intravascular coagulopathy; so these items are intrinsic to the score.
MCV was not incorporated in the French score.
Results correspond to those of the derivation cohort and those of a validation by (French score) the bootstrap resampling technique (internal validation) (Coppo et al,12 Bendapudi et al,13 and manuscript in preparation), or (PLASMIC score) different samples of patients from the same institution (internal validation) or from a different institution (external validation).12, 13